Shareholders of Supriya Lifescience have approved the re-appointment of Mr. Balasaheb Sawant as Whole Time Director and Key Managerial Personnel for a term of three years.

The special resolution was passed with a requisite majority through remote e-voting conducted between July 23, 2026 and August 21, 2026. Mr. Sawant’s tenure will run from May 26, 2026 to May 25, 2029.

Voting Results

The company received votes from 361 shareholders representing 58,281,483 shares out of a total outstanding equity base of 80,482,800 shares as on the record date of July 17, 2026. This represents a participation rate of 72.41%.

Promoter group shareholders voted unanimously in favor, casting all 54,967,715 polled votes toward the resolution. Public institutional investors showed strong support with 94.38% of their polled votes in favor, while public non-institutional shareholders supported the resolution at 98.16%.

What the Numbers Show

The voting pattern highlights a clear divergence in engagement levels between promoter and public shareholders. While promoters achieved near-total participation (100% of held shares voted), public non-institutional shareholders participated at less than 1%, casting only 146,673 votes against their holding of over 16 million shares. Despite this low turnout from retail non-institutional holders, the overwhelming support from promoters and institutions ensured the resolution passed with 99.69% affirmative votes.

Supriya Lifescience reported robust top-line growth in its first quarter of FY27, with revenue rising 31% year-on-year to ₹190 crore. Despite the strong sales performance, profitability metrics contracted due to transient operational disruptions, including regional water scarcity and revised solar power policies in Maharashtra.

The company’s EBITDA stood at ₹47 crore, marking an 8.1% decline from ₹52 crore in the corresponding quarter of FY26. Consequently, EBITDA margins compressed to 25%, down from previous levels. Net profit after tax (PAT) also decreased to ₹24 crore, compared to ₹35 crore in Q1FY26, resulting in a PAT margin of 12.7%.

Operational Headwinds

Management attributed the margin compression to specific, temporary factors that added approximately ₹10.5 crore to operating costs during the quarter. The delayed onset of monsoons caused significant water shortages at the Lote MIDC facility, leading to a deferment of sales worth approximately ₹35 crore. Additionally, changes in the Maharashtra government’s solar power policy resulted in higher fuel and power costs, impacting EBITDA by roughly ₹8 crore. Management noted that a portion of this power cost increase was retrospective, relating to backdated collections between March and July 2025.

Financial Performance

Excluding these one-off impacts, management stated that margins would have remained within the guided range. The company reaffirmed its full-year guidance, targeting revenue close to ₹1,000 crore and EBITDA margins between 33% and 35% for FY27.

What the Numbers Show

A notable divergence exists between the company’s revenue growth and its profit expansion. While revenue surged by 31%, net profit declined by over 30%. This disconnect highlights the severity of the temporary cost headwinds; the ₹10.5 crore in additional operating costs effectively erased the operational leverage typically gained from such significant top-line growth. Furthermore, exports continued to dominate the revenue mix, contributing 81% of total sales, underscoring the company’s heavy reliance on international markets despite domestic operational challenges.

Strategic Updates and Capex

Exports remained a key growth driver, with Asia contributing 39% of revenue, followed by Europe at 35% and Latin America at 20%. The company has launched two new anesthetic liquid inhalation products from its Ambernath facility and expects two ADHD product launches to strengthen its portfolio further. Development on contrast media products is on track for launch in the second half of FY27.

Capital expenditure for the quarter stood at ₹16.58 crore, primarily directed toward maintenance, smaller projects, and the Isambe project. The company has received all necessary clearances for the Patalganga land acquisition, with Phase-1 development earmarked for ₹200 crore. This phase will include two API blocks and two formulation blocks. Management clarified that boundary wall construction has already begun, signaling the start of ground-breaking activities.

Balance Sheet and Outlook

As of June 30, 2026, inventory levels were reported between ₹230 crore and ₹240 crore. Management explained that this elevated inventory position stems from pre-maintenance stockpiling, which is now being liquidated as the planned annual shutdown was revised to a phased maintenance approach to minimize production impact. Cash reserves stood at approximately ₹150 crore in fixed deposits and mutual funds, providing ample liquidity for ongoing capital requirements without utilizing working capital limits beyond letters of credit and bank guarantees.